Back to compounds

COMPOUND PROFILE / PEPTIDES & ANALOGUES

Amycretin.

Research draft

Amycretin is a single-molecule GLP-1 and amylin receptor agonist studied for obesity.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Overview

Amycretin is a single-molecule GLP-1 and amylin receptor agonist studied for obesity.

CLASSIFICATIONPeptides & analogues
MOLECULAR / SEQUENCE INFONot specified
PRIMARY CONTEXTCompound

Mechanism

It combines incretin and amylin-related satiety signalling.

Human research

Randomised early human trials reported weight reduction. Oral and subcutaneous formulations must be assessed separately.

Preclinical & other research

Receptor and animal work supports the dual-action rationale.

Safety & unknowns

Gastrointestinal tolerability and longer-term outcomes require continued assessment.

Regulatory status

Investigational in the sources reviewed; cross-link NNC0487-0111 after identity confirmation.

Reported use & evidence

Research profile draft

The supplied Amycretin profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Explore more compounds